Form 4: Nektar Therapeutics Chief R&D Officer Sells Shares to Cover Tax Obligations

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 51,115 shares of common stock to cover tax obligations related to vesting RSUs.

Summary

• Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 51,115 shares of common stock on December 19, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $0.94, with individual trades ranging from $0.89 to $1.00.
• Following the transaction, Zalevsky directly owns 326,904 shares of Nektar Therapeutics stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology and pharmaceutical industries.
• Similar transactions are regularly reported by executives at companies like Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Nektar Therapeutics, insider trading, stock sale, Jonathan Zalevsky, RSU, tax obligations, NKTR, Chief R&D Officer